Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 3/20 | 1.00 |
| ▸ | PLG | P00747 | 1/20 | 0.59 |
| ▸ | F11 | P03951 | 1/20 | 0.59 |
| ▸ | ELANE | P08246 | 4/20 | 0.58 |
| ▸ | F2 | P00734 | 3/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 5/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6729131 | 1.00 | KLK7 (1.00) | KLK7PLGF11ELANEF2 | |
| SCHEMBL18395341 | 1.00 | KLK7 (1.00) | KLK7PLGF11ELANEF2 | |
| SCHEMBL13562895 | 1.00 | KLK7 (1.00) | KLK7PLGF11ELANEF2 | |
| SCHEMBL18698806 | 1.00 | KLK7 (1.00) | KLK7PLGF11ELANEF2 | |
| SCHEMBL19336662 | 1.00 | KLK7 (1.00) | KLK7PLGF11ELANEF2 | |
| SCHEMBL18698808 | 1.00 | KLK7 (1.00) | KLK7PLGF11ELANEF2 | |
| SCHEMBL15081576 | 1.00 | KLK7 (1.00) | KLK7PLGF11ELANEF2 | |
| SCHEMBL13554878 | 1.00 | KLK7 (1.00) | KLK7PLGF11ELANEF2 | |
| SCHEMBL6729197 | 0.97 | KLK7 (0.95) | KLK7PLGF11ELANEF2 | |
| SCHEMBL14845603 | 0.97 | KLK7 (0.95) | KLK7PLGF11ELANEF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493512-B2 | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9278997-B2 | Processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20140080995-A1 | Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | NOVARTIS AG (CH) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080995-A1 | Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | VIP, NPPA, PTMS | KLK7 1205/4885PLG 1440/4885F11 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.